- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06915753
Säkerhet och preliminär anti-tumöraktivitet av TYRA-430 i avancerat hepatocellulärt karcinom och andra solida tumörer med aktiverande FGF/FGFR-vägavvikelser (SURF431)
En multicenter, öppen etikett, första-i-mänsklig studie av Tyra-430 i avancerat hepatocellulärt karcinom och andra solida tumörer med aktiverande FGF/FGFR-vägavvikelser
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is an open-label, multi-center, first-in-human, Phase 1 global study of TYRA-430, a first-in-class, selective, reversible fibroblast growth factor receptor (FGFR) 4 and 3 inhibitor, in locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors that contain FGF/FGFR pathway aberrations.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Lara Balick
- Telefonnummer: 929-792-5633
- E-post: TyraClinicalTrials@tyra.bio
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90033
- Rekrytering
- USC Norris Comprehensive Cancer Center
-
San Francisco, California, Förenta staterna, 94158
- Rekrytering
- UCSF Medical Center at Mount Zion
-
Stanford, California, Förenta staterna, 94305
- Rekrytering
- Stanford Cancer Institute
-
-
Kansas
-
Westwood, Kansas, Förenta staterna, 66205
- Rekrytering
- The University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21205
- Rekrytering
- John Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Mass General Cancer Center
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Rekrytering
- Karmanos Cancer Institute
-
-
New York
-
New York, New York, Förenta staterna, 10043
- Rekrytering
- Columbia University Irving Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Indragen
- Sarah Cannon Research Institute Oncology Partners
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2C4
- Rekrytering
- University Health Network Princess Margaret Cancer Center
-
-
-
-
-
Seoul, Sydkorea
- Rekrytering
- Samsung Medical Center
-
Seoul, Sydkorea
- Rekrytering
- Seoul National University Hospital
-
Seoul, Sydkorea
- Rekrytering
- Asan Medical Center
-
Seoul, Sydkorea
- Rekrytering
- Severance Hospital, Yonsei University Health System
-
-
-
-
-
Taipei, Taiwan
- Rekrytering
- Taipei Veterans General Hospital
-
Taipei, Taiwan
- Rekrytering
- National Taiwan University Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
All Patients:
- Age ≥ 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
- Adequate end organ function.
- Ability to swallow oral formulations.
- Ability to understand and willingness to sign the ICF.
Part A:
-
Histologically confirmed locally advanced unresectable/metastatic HCC or histologically confirmed advanced solid tumor with documented FGF/FGFR pathway alterations
-
For participants with histologically confirmed locally advanced or metastatic HCC:
- Barcelona Clinic Liver Cancer (BCLC) stage B that is not eligible for locoregional therapy, or stage C.
- Child-Pugh Score class A
-
Must have previously received SOC appropriate for their tumor type. Any number of prior therapies, including FGFR inhibitors, are permitted.
-
Agree to provide archival tumor tissue, if available. If an archived specimen is not available, a biopsy is not required.
Part B, Cohort 1:
- Histologically confirmed locally advanced/metastatic HCC who have previously received standard of care.
- Barcelona Clinic Liver Cancer (BCLC) stage B that is not eligible for locoregional therapy, or stage C.
- Child-Pugh Score class A
- Availability of an archival formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen for submission to sponsor-designated central laboratory for FGF19 IHC testing.
- At least 1 measurable lesion by RECIST v1.1.
Part B, Cohort 2:
- Histologically confirmed advanced solid tumor except FGFR3-altered urothelial carcinoma and primary central nervous system tumors who have previously received standard of care. Note: Participants with confirmed diagnosis of locally advanced or metastatic HCC are not eligible for Cohort 2.
- Must have an eligible activating gain-of-function alteration in the FGFR4 gene, or focal amplifications of FGF19
- Archival tumor tissue biopsy specimen , if available. If a tissue biopsy specimen is not available, a biopsy is not required.
- At least 1 measurable lesion by RECIST v1.1.
Key Exclusion Criteria:
All Patients:
-
Have disease that is suitable for local therapy administered with curative intent.
-
Have not recovered from reversible toxicity of prior anticancer therapy to < Grade 1 or baseline (except toxicities that are not clinically significant or not expected to resolve, including but not limited to, alopecia, fatigue, skin discoloration, or Grade 1 neuropathy).
-
Have received the following anticancer therapy:
- Any immunotherapy or other antibody therapy within 28 days prior to the first dose of the study drug.
- A TKI < 5 days or 5X the terminal Phase elimination half-lives, whichever is longer, prior to the first dose of TYRA-430.
- Other systemic therapy not listed above < 14 days prior to the first dose of the study drug.
-
Participant discontinued a prior anti-FGFR therapy due to significant toxicity
-
Has a serum phosphorus level > upper limit of normal (ULN) during screening that remains >ULN despite medical management.
-
History of or current uncontrolled cardiovascular disease.
-
Active, symptomatic, or untreated brain metastases.
-
Have a diagnosis of primary CNS malignancies.
-
Gastrointestinal disorders that will affect oral administration or absorption of TYRA-430.
-
Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.
-
Any reason that, in the view of investigator, would substantially impair the ability of the participant to comply with study procedures and increase the risk to the participant.
Part B, Cohort 1:
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
- Prior treatment with pan-FGFR inhibitors or FGFR4-selective inhibitors.
Part B, Cohort 2:
- Histologically confirmed locally advanced/metastatic HCC.
- Histologically confirmed urothelial cancer.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part A - Dose Escalation
Dose escalation of TYRA-430 as monotherapy at various dose levels. |
Oral TYRA-430 given daily. |
|
Experimentell: Part B - Cohort 1 Dose Expansion
Dose expansion group for TYRA-430 monotherapy in advanced HCC at a dose(s) determined in Part A. |
Oral TYRA-430 given daily. |
|
Experimentell: Part B - Cohort 2 Dose Expansion
Dose expansion group for TYRA-430 monotherapy in advanced solid tumors at a dose(s) determined in Part A. |
Oral TYRA-430 given daily. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Maximum tolerated dose (MTD)
Tidsram: Up to 1 year
|
MTD determination: dose limiting toxicity (DLT) rate in the first 28-day cycle |
Up to 1 year
|
|
Rate and severity of adverse events of TYRA-430 as monotherapy
Tidsram: First dose of study drug through 28 days after the last dose of study drug
|
Number of participants with TEAEs as assessed by CTCAE, v5.0 |
First dose of study drug through 28 days after the last dose of study drug
|
|
Recommended Phase 2 dose(s) of TYRA-430
Tidsram: Up to 2 years
|
To determine recommended Phase 2 dose(s) of TYRA-430 |
Up to 2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Cmax
Tidsram: Upp till 2 år
|
Upp till 2 år
|
|
|
Tmax
Tidsram: Upp till 2 år
|
Upp till 2 år
|
|
|
AUC0-LAST
Tidsram: Upp till 2 år
|
Upp till 2 år
|
|
|
Auctau
Tidsram: Upp till 2 år
|
Upp till 2 år
|
|
|
AUC0-∞
Tidsram: Upp till 2 år
|
Upp till 2 år
|
|
|
Vd/f
Tidsram: Upp till 2 år
|
Upp till 2 år
|
|
|
Kl/f
Tidsram: Upp till 2 år
|
Upp till 2 år
|
|
|
T1/2
Tidsram: Upp till 2 år
|
Upp till 2 år
|
|
|
Overall Response Rate (ORR)
Tidsram: Up to 3.5 years
|
The proportion of patients who experience a best response of confirmed CR or PR per RECIST 1.1 |
Up to 3.5 years
|
|
Duration of Response (DOR)
Tidsram: Up to 3.5 years
|
Time from first investigator-assessed response to radiographic disease progression or death. |
Up to 3.5 years
|
|
Disease Control Rate (DCR)
Tidsram: Up to 3.5 years
|
Best response of CR, PR, or SD per RECIST v1.1 > 12 months. |
Up to 3.5 years
|
|
Time to Response (TTR)
Tidsram: Up to 3.5 years
|
The median time from the start of therapy to first response in confirmed responders. |
Up to 3.5 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Doug Warner, MD, Tyra Biosciences, Inc
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Neoplasmer efter plats
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Leversjukdomar
- Neoplasmer, körtel och epitel
- Adenocarcinom
- Neoplasmer i levern
- Neoplastiska processer
- Carcinom
- Patologiska tillstånd, tecken och symtom
- Karcinom, hepatocellulärt
- Neoplasma Metastas
Andra studie-ID-nummer
- TYR430-101
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .